Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Meyer Handelman Co.

Meyer Handelman Co. lessened its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 11.5% in the third quarter, Holdings Channel.com reports. The fund owned 34,608 shares of the medical research company’s stock after selling 4,500 shares during the quarter. Meyer Handelman Co.’s holdings in Edwards Lifesciences were worth $2,284,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. GLOBALT Investments LLC GA acquired a new stake in shares of Edwards Lifesciences during the fourth quarter valued at approximately $945,000. V Square Quantitative Management LLC raised its stake in Edwards Lifesciences by 31.6% during the 4th quarter. V Square Quantitative Management LLC now owns 11,047 shares of the medical research company’s stock valued at $842,000 after purchasing an additional 2,652 shares during the period. Tortoise Investment Management LLC boosted its position in shares of Edwards Lifesciences by 140.2% in the fourth quarter. Tortoise Investment Management LLC now owns 1,441 shares of the medical research company’s stock worth $110,000 after buying an additional 841 shares during the period. Richardson Financial Services Inc. purchased a new position in shares of Edwards Lifesciences during the fourth quarter valued at $64,000. Finally, Wellington Management Group LLP raised its position in Edwards Lifesciences by 2.4% during the fourth quarter. Wellington Management Group LLP now owns 16,827,510 shares of the medical research company’s stock valued at $1,283,098,000 after buying an additional 393,109 shares during the period. 79.46% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have commented on EW. Canaccord Genuity Group lowered their target price on Edwards Lifesciences from $77.00 to $66.00 and set a “hold” rating on the stock in a research note on Monday, October 7th. StockNews.com downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Thursday, July 25th. Barclays cut their target price on shares of Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating for the company in a research report on Monday, September 9th. Morgan Stanley restated an “equal weight” rating and set a $70.00 price target on shares of Edwards Lifesciences in a report on Friday. Finally, JPMorgan Chase & Co. cut Edwards Lifesciences from an “overweight” rating to a “neutral” rating and reduced their price objective for the company from $105.00 to $72.00 in a research report on Thursday, July 25th. Seventeen research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Edwards Lifesciences has an average rating of “Hold” and a consensus price target of $75.77.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 11th. The stock was sold at an average price of $66.77, for a total transaction of $333,850.00. Following the sale, the vice president now directly owns 46,936 shares in the company, valued at approximately $3,133,916.72. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction dated Wednesday, September 11th. The shares were sold at an average price of $66.77, for a total value of $333,850.00. Following the sale, the vice president now owns 46,936 shares of the company’s stock, valued at $3,133,916.72. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Daveen Chopra sold 1,250 shares of the firm’s stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total transaction of $87,437.50. Following the transaction, the vice president now owns 29,333 shares of the company’s stock, valued at approximately $2,051,843.35. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 11,250 shares of company stock valued at $751,688 in the last quarter. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Down 0.2 %

EW opened at $68.13 on Friday. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12. The business has a 50 day moving average of $67.13 and a 200-day moving average of $80.08. The stock has a market capitalization of $41.06 billion, a price-to-earnings ratio of 29.37, a P/E/G ratio of 2.83 and a beta of 1.13. The company has a current ratio of 3.71, a quick ratio of 2.87 and a debt-to-equity ratio of 0.08.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Wednesday, July 24th. The medical research company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.69 by $0.01. The company had revenue of $1.63 billion for the quarter, compared to analyst estimates of $1.65 billion. Edwards Lifesciences had a net margin of 24.55% and a return on equity of 22.35%. The business’s quarterly revenue was up 6.7% on a year-over-year basis. During the same period last year, the business posted $0.66 EPS. As a group, sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.71 earnings per share for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.